Andrew Hirsch

Prior to joining Avila, Mr. Andrew Hirsch served in roles of increasing responsibility during his nearly ten year tenure at Biogen Idec, most recently as Vice President, Corporate Strategy and M&A, where he played a key role in developing a new strategy for the company. Prior to that, Mr. Hirsch held various positions in the finance organization including leading the company’s Business Planning and Investor Relations functions. In addition he served as Program Executive in neurology leading the development teams for the company’s BG-12, Avonex®, and Tysabri® programs. Prior to joining Biogen Idec, Mr. Hirsch led business development for a software start-up company and spent several years in management consulting at both Stern Stewart & Co. and The Parthenon Group. He holds a Masters of Business Administration from the Tuck School at Dartmouth College.

Andrew Hirsch is the VP, Chief Financial Officer at Avila Therapeutics, based in United States, North America. With a background in Biotechnology, Andrew Hirsch has a rich history of leadership and innovation.Andrew Hirsch studied MBA General Management at Tuck School of Business at Dartmouth College. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.